Shares of Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) have earned an average rating of “Hold” from the thirty research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, sixteen have issued a hold recommendation, eleven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $65.46.
A number of research analysts have recently commented on the company. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Rothschild & Co Redburn raised their target price on Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 19th. Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Finally, TD Cowen started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock.
Read Our Latest Research Report on Bristol Myers Squibb
Insider Activity at Bristol Myers Squibb
In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Julia Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is currently owned by insiders.
Institutional Trading of Bristol Myers Squibb
A number of large investors have recently bought and sold shares of BMY. Financial Freedom LLC purchased a new position in Bristol Myers Squibb in the 3rd quarter valued at $26,000. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $27,000. Addison Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $32,000. William Mack & Associates Inc. acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $35,000. Finally, Cavanaugh Group Inc. acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol Myers Squibb Stock Performance
Shares of BMY stock opened at $58.81 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The firm has a fifty day moving average price of $61.45 and a 200 day moving average price of $60.44. The company has a market cap of $120.22 billion, a P/E ratio of 13.04, a PEG ratio of 0.30 and a beta of 0.20. Bristol Myers Squibb has a 12 month low of $45.52 and a 12 month high of $68.64.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.63 earnings per share. Sell-side analysts predict that Bristol Myers Squibb will post 6.46 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.88%.
Key Bristol Myers Squibb News
These are some of the BMY news items that stood out recently:
- Neutral Sentiment: BMS reported initial Phase 3 ADEPT data for KarXT in psychosis associated with Alzheimer’s disease, an area with a significant treatment gap. The available report does not provide results on efficacy or safety, so the investment impact will depend on the full data. Article: Bristol Myers Squibb Is Pushing Deeper Into Neuroscience
- Neutral Sentiment: The company highlighted more than 90 updates across blood cancers and rare hematologic disorders at the ASH meeting. This underscores the breadth of its pipeline, but the reports provided do not specify data that would indicate a clear change in commercial prospects. Article: Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
- Negative Sentiment: Dividend-focused coverage points to a looming Eliquis patent-related revenue cliff, a risk to earnings and the sustainability of shareholder payouts as the drug faces future competition. Recent weakness in BMY shares despite pipeline news also signals investor caution. Article: 3 Big Pharma Dividend Stocks Built for Retirement Income
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Further Reading
- Five stocks we like better than Bristol Myers Squibb
- Bargain Hunting: Why Off-Price Retail Is Winning
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
